Fortress Biotech Reports Q2 2024 Financial Highlights
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
- Latest
- Trending
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
"Patterson Companies posts 1% Q4 internal sales growth despite cybersecurity hit, highlights strong pet and production animal markets for future."
Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.